BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Arbor Pharmaceuticals Release: New Hospitalization Data from the African-American Heart Failure Trial to be Presented at the American College of Cardiology's 2012 Scientific Session


3/27/2012 9:01:04 AM

ATLANTA, March 26, 2012 /PRNewswire/ -- Arbor Pharmaceuticals, a specialty pharmaceutical company based in Atlanta, GA, announced today that Dr. Inder Anand, MD will present new hospitalization data from the landmark African-American Heart Failure Trial (A-HeFT) at the 2012 American College of Cardiology Scientific Session in Chicago, Illinois on March 26, 2012.

The A-Heft Trial, entitled, "Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure" was published in the New England Journal of Medicine in November 2004. The A-HeFT trial reported landmark outcomes of reduced mortality, reduced time to first hospitalization and improvement in functional status in black heart failure patients when the fixed-dosed combination of isosorbide dinitrate and hydralazine was added to the current course of standard therapy for the treatment of heart failure.

These outcomes led to the early termination of the A-HeFT trial and a subsequent update to the 2009 American College of Cardiology Foundation and American Heart Association treatment guidelines for heart failure.

The fixed-dose combination of isosorbide dinitrate and hydralazine is marketed by Arbor Pharmaceuticals under the brand name of BiDil®.

BiDil is indicated for the treatment of heart failure as an adjunct to standard therapy in self-identified black patients to improve survival, to prolong time to hospitalization for heart failure and to improve patient-reported functional status.

See full Prescribing Information at www.bidil.com

About Arbor Pharmaceuticals, Inc.
Arbor Pharmaceuticals, headquartered in Atlanta, Georgia, is a specialty pharmaceutical company currently focused on the cardiovascular and pediatric markets. The company intends to become a leading specialty pharmaceutical company by actively licensing, developing and commercializing late-stage products for specialty focused conditions. Arbor currently markets multiple NDA and ANDA approved products with several more in development.

For more information regarding Arbor Pharmaceuticals, visit www.arborpharma.com or send email inquiries to info@arborpharma.com.

SOURCE Arbor Pharmaceuticals, Inc.


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->